We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Testing Evaluated for Chlamydia and Gonorrhea

By LabMedica International staff writers
Posted on 23 Nov 2016
Print article
Image: The GeneXpert CT/NG rapid diagnostic test cartridge (Photo courtesy of Cepheid).
Image: The GeneXpert CT/NG rapid diagnostic test cartridge (Photo courtesy of Cepheid).
Prolonged turnaround time of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) test results may delay time to notification and treatment of test-positive patients and result in unnecessary antimicrobial use in test-negative patients.

Nonculture methods, including nucleic acid amplification tests (NAAT), are widely available for the detection of genital NG/CT and are the preferred diagnostic tests, but with traditional NAAT, many health care facilities have a turnaround time between 1 and 4 days for results of NG/CT. This prolonged time to results impacts time to patient and partner notification as well as treatment for test-positive patients who do not receive empiric therapy.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) and their colleagues evaluated the impact of NG/CT rapid diagnostic testing (RDT) in an urban emergency department (ED) on treatment appropriateness, time to notification, and cost. They tested 200 patients in December 2013–January 2014 by traditional methods and these were compared with 200 patients in December 2014–January 2015 by RDT. Samples utilized by the ED included male urine or urethral samples and female endocervical samples.

Traditional testing was performed using the Gen-Probe Aptima Combo 2 for NG/CT Assay (Hologic, Bedford, MA, USA). The RDTs were performed using the GeneXpert CT/NG assay (Cepheid, Sunnyvale, CA, USA). The RDT was validated compared with the traditional testing method with sensitivity and specificity. A total of 53 patient specimens were collected and tested including male and female first-catch urine samples, patient-collected vaginal swabs, and provider-collected endocervical swabs.

The scientists found that there was a significant increase in treatment appropriateness in the RDT group, 72.5% versus 60% and time to results notification was significantly faster with a median of 17.4 versus 51.5 hours. Availability of test result prior to discharge was associated with increased treatment appropriateness. They also reported that the RDT would save approximately USD 37,000 annually. Of the 200 patients tested in the RDT group, only 40 (20%) were present in the ED at the time their results became available.

The authors concluded that implementation of a RDT for NG/CT in the ED significantly improved initial treatment appropriateness by sparing unnecessary antimicrobial use, decreased time to patient notification, and resulted in cost savings. Having test results prior to patient discharge from the ED was independently associated with receiving appropriate treatment. Interventions to increase the proportion of tests resulted prior to discharge are warranted to improve utilization of the RDT. The findings of this evaluation support the use of the NG/CT RDT as a component of antimicrobial stewardship in the ED. The study was published on October 18, 2016, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Cleveland Clinic
Hologic
Cepheid
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.